ecancermedicalscience

Short Communication

Clinical research in oncology: in memory of Professor Gordon McVie

13 Jan 2022
Ian F Tannock

Gordon McVie campaigned throughout his career for merging scientific and clinical expertise and for investigating the underlying pharmacokinetics and pharmacodynamics in clinical trials. This need remains highly relevant today when most cancer clinical trials investigate agents that target a known molecular pathway, yet anticancer drug development has changed minimally from that used for chemotherapy when more was better and substantial toxicity inevitable. Here, I summarise some common problems that confound current drug development, including problems in interpreting results of phase 3 randomised trials, as well as trials investigating personalised medicine.

Related Articles

Isabel Saffie Vega, Jorge Sapunar Zenteno, Felipe Buscaglia Fernandez, Felipe Reyes Cosmelli, Rodrigo Lagos Chavez, Badir Chahuán Manzur
Soo-Peng Teoh, Yee-Yin Hoo, Raúl Murillo, María Zuluaga, Audrey Tsunoda, Dorothy Lombe, Richard Sullivan, Nirmala Bhoo-Pathy
Paromita Roy, Lateef Zameer, Debdeep Dey, Jayati Datta, Anand Bardia, Deepak Mishra
Julia Downing, Nixon Niyonzima, Eddie Mwebesa, Innocent Mutyaba, Lisa Christine Irumba, Ludoviko Zirimenya, Diana Basirika, Immacula Mbarusha, Charity Kobusingye, Margaret Happy, Alfred Jatho, Dorothy Olet Adong, Cynthia Kabagambe, Collins Mpamani, Zaitun Nalukwago, Zipporah Kyomuhangi, Joyce Zalwango, Jackson Orem, Mark Mwesiga